Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Data from FREEDOM-301 Study for LEVADEXâ„¢ Orally Inhaled Migraine Drug Published in ‘Headache’

April 7, 2011 By Bio-Medicine.Org

MOUNTAIN VIEW, Calif., April 7, 2011 /PRNewswire/ — MAP
Pharmaceuticals, Inc. (Nasdaq:
MAPP) today announced the publication of results from the Phase
3 FREEDOM-301 study of  LEVADEX™ orally inhaled migraine
drug in the peer-reviewed journal ‘Headache.’ The manuscript,
titled MAP0004, Orally Inhaled DHE: A Randomized, Controlled Study
in the Acute Treatment of Migraine, has been posted online and will
appear in the April edition, Volume 51, Issue 4 of Headache: The
Journal of Head and Face Pain. LEVADEX is an investigational acute
therapy for migraine that has completed Phase 3 clinical
development.

“There is general dissatisfaction with existing acute treatment
options for migraine because of slow onset of action, inadequate
pain relief, and high recurrence rates. Based on the results from
the FREEDOM-301 study, LEVADEX has the potential to address many of
the unmet needs of migraine sufferers,” said Sheena Aurora, M.D., a
FREEDOM-301 clinical study investigator, director of the Swedish
Headache Center and assistant professor of neurology at the
University Of Washington School of Medicine. 

In the FREEDOM-301 study, the efficacy assessment focused on the
four major symptoms of migraine at the standard two hour time point
for acute migraine studies. All four co-primary endpoints for
LEVADEX were met at two hours:

Pain relief was observed in 59% of patients in the LEVADEX
treatment group compared with 35% in the placebo group
(p<0.0001) Phonophobia free was observed in 53% of patients in
the LEVADEX treatment group compared with 34% for the placebo group
(p<0.0001) Photophobia free was observed in 47% of patients in
the LEVADEX treatment group compared with 27% for the placebo group
(p<0.0001) Nausea free was observed in 67% of  patients in
the LEVADEX treatment group compared with 59% for the placeb

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech